All data are based on the daily closing price as of May 8, 2026
l
Lunit
328130.KQ
13.50 USD
-0.87
-6.05%
Overview
Last close
13.50 usd
Market cap
1.00B usd
52 week high
58.23 usd
52 week low
13.50 usd
Target price
10.24 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
17.7972
Price/Book Value
11.2576
Enterprise Value
1.12B usd
EV/Revenue
19.7025
EV/EBITDA
-45.3273
Key financials
Revenue TTM
56.76M usd
Gross Profit TTM
56.76M usd
EBITDA TTM
-49.70M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
256.40M usd
Net debt
54.94M usd
About
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.